ReviewCancers2023
Pediatric Rhabdomyosarcomas of the Genitourinary Tract.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Aggressive prostatic embryonal rhabdomyosarcoma in an adolescent: A case report and short review.Urology case reports · 2026Article
- Adult embryonal rhabdomyosarcoma (botryoid subtype) of the ureter: A case report.Urology case reports · 2026Article
- Clinicopathological Characteristics and Outcomes of Genitourinary Rhabdomyosarcoma in Two Girls.Clinical case reports · 2026Article
- 18 F-FDG PET/CT in Rhabdomyosarcoma of the Prostate in an Infant.Clinical nuclear medicine · 2026Article
- Primary intracranial rhabdomyosarcoma: A systematic review of existing literature from 2000 to 2024.Pakistan journal of medical sciences · 2025Review
- Letter to "Long-term urinary and sexual outcomes in pediatric genitourinary rhabdomyosarcoma survivors: a qualitative study".Pediatric surgery international · 2025Article
- Atypical Pelvic Tumors in Children.Cancers · 2025Article
- Delayed diagnosis for DICER1-associated embryonal rhabdomyosarcoma in the cervix for a 15-year-old girl: a case report.Gynecology and pelvic medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric and adolescent population, with 350 new cases diagnosed each year. While they can develop anywhere in the body, the genitourinary tract is the second most common primary location for an RMS to develop. Overall survival has improved through the increased use of protocols and multidisciplinary approaches. However, the guidelines for management continue to change as systemic and radiation therapeutics advance. Given the relative rarity of this disease compared to other non-solid childhood malignancies, healthcare providers not directly managing RMS may not be familiar with their presentation and updated management. This review aims to provide foundational knowledge of the management of RMSs with an emphasis on specific management paradigms for those arising from the genitourinary tract. The genitourinary tract is the second most common location for an RMS to develop but varies greatly in symptomology and survival depending on the organ of origin. As the clinical understanding of these tumors advances, treatment paradigms have evolved. Herein, we describe the breadth of presentations for genitourinary RMSs with diagnostic and treatment management considerations, incorporating the most recently available guidelines and societal consensus recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.